Cerevel Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Cerevel Therapeutics's estimated annual revenue is currently $94.6M per year.
- Cerevel Therapeutics's estimated revenue per employee is $281,400
- Cerevel Therapeutics's total funding is $1.4B.
Employee Data
- Cerevel Therapeutics has 336 Employees.
- Cerevel Therapeutics grew their employee count by 2% last year.
Cerevel Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP | Reveal Email/Phone |
2 | Chief Business Development and Strategic Operations Officer | Reveal Email/Phone |
3 | SVP, Finance and Chief Accounting Officer | Reveal Email/Phone |
4 | SVP, Head Global Regulatory and Access Solutions | Reveal Email/Phone |
5 | Head - Global Value & Access | Reveal Email/Phone |
6 | SVP, Clinical Operations and Data Management | Reveal Email/Phone |
7 | Head Information Technology Infrastructure & Operations at Cerevel Therapeutics | Reveal Email/Phone |
8 | SVP Safety Assessment and Research Operations | Reveal Email/Phone |
9 | Executive Assistant, Office the Chief Legal Officer | Reveal Email/Phone |
10 | Head Biostatistics | Reveal Email/Phone |
Cerevel Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is Cerevel Therapeutics?
Cerevel Therapeutics is a biopharmaceutical company focused on developing new therapies to treat disorders of the central nervous system (CNS). The company has a portfolio of experimental neuroscience therapies, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders, including Parkinsonￃﾢ￢ﾂﾬ￢ﾄﾢs, Alzheimerￃﾢ￢ﾂﾬ￢ﾄﾢs, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.
keywords:N/A
$1.4B
Total Funding
336
Number of Employees
$94.6M
Revenue (est)
2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cerevel Therapeutics News
The 69 rating InvestorsObserver gives to Cerevel Therapeutics Holdings Inc (CERE) stock puts it near the top of the Biotechnology industry.
Cerevel Therapeutics Holdings Inc (CERE) stock is higher by 112.88% over the last 12 months, and the average rating from Wall Street...
Oral presentation to highlight preclinical data demonstrating robust antiepileptic activity for darigabat in drug-resistant focal epilepsy.
Cerevel Therapeutics Announces Pricing of $350 Million Public Offering of Common Stock CAMBRIDGE, Mass., July 1, 2021 (GLOBE NEWSWIRE) - Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing ...
CAMBRIDGE, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten public offering of 14,000,000 shares of commo ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $102.1M | 336 | 8% | N/A |
#2 | $87.1M | 336 | 6% | $180M |
#3 | $136.5M | 336 | N/A | N/A |
#4 | $87.1M | 336 | 6% | $180M |
#5 | $93.2M | 339 | 7% | N/A |